Search Results - "Romera, J. Lao"

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study by Gavilá, J., De La Haba, J., Bermejo, B., Rodríguez-Lescure, Á., Antón, A., Ciruelos, E., Brunet, J., Muñoz-Couselo, E., Santisteban, M., Rodríguez Sánchez, C. A., Santaballa, A., Sánchez Rovira, P., García Sáenz, J. Á., Ruiz-Borrego, M., Guerrero-Zotano, A. L., Huerta, M., Cotes-Sanchís, A., Lao Romera, J., Aguirre, E., Cortés, J., Llombart-Cussac, A.

“…Purpose To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients…”
Get full text

P5-13-16: Reduction in PET Uptake-Value Is an Early Predictor for Response to Neoadjuvant Therapy Including Anthracycline and Taxane in Stage II-IIIa Breast by Lao, Romera J, Puértolas, Hernandez T, Godoy, Molias A, Alvarez, Alejandro M, Madani, Perez J, Garcia, Mur C, Ubieto, MA, Cebollero, de Miguel A, Artal, Cortes A, Anton, Torres A

“…Abstract Background and Aim: Reduction in FDG-PET uptake as response predictor after induction chemotherapy for breast cancer has been described. Our aim was…”
Get full text

P2-09-08: FDG-PET in the Staging of the Axilla in Women with Breast Cancer Treated with Primary Chemotherapy by Lao, Romera J, Puértolas, Hernandez T, Alvarez, Alejandro M, Godoy, Molias A, Hernandez, Garcia A, Millastre, Bocos E, Garcia, Mur C, Ubieto, Laguarda MA, Artal, Cortes A, Anton, Torres A

“…Abstract Background FDG-PET has proven to be useful during the initial staging of several tumor types. The aim of the present study was to assess the accuracy…”
Get full text

P5-13-04: Changes in Phosphorylation Status at VEGFR2 and Basal Tumor Hypoxic Volume Assessed by Misonidazol (MISO) Positron Emission Tomography (PET/CT) as Potential Biomarkers for Predicting Response to Bevacizumab in Breast Cancer by Garcia-Foncilla, J, Garcia-Velloso, MJ, Dominguez, I, Morales, S, Hernando, B, Sanchez, R, Alvarez, I, Anton, A, Illarramendi, JJ, De, Juan A, Martinez, P, Lahuerta, A, Llombart, A, Garcia-Gonzalez, M, Lao, Romera J, Purtolas, T, Scherer, S, Sabariz, Luis, Lopez-Vega, JM, Galve, E, Plazaola, A, Boni, V

“…Abstract Background: To evaluate the expression of novel putative biomarkers as predictors of benefit from bevacizumab in stage II-III, previously untreated…”
Get full text

P2-08-05: Use of Dynamic Contrast-Enhanced MR Imaging To Predict Pathological Response in Primary Breast Cancer by Boni, V, Pina, LJ, Hernando, B, Lopez-Vega, JM, Calvo, EG, Plazaola, A, Morales, S, Anton, A, Sanchez-Gomez, RM, Alvarez, I, Illarramendi, JJ, De, Juan A, Martinez, P, Llombart, A, La, Huerta A, Dominguez, I, Garcia-Velloso, MJ, Garcia-Gonzalez, M, Lao, Romera J, Puertolas, T, Scherer, S, Sabariz, L, Garcia-Foncillas, J

“…Abstract Purpose: To investigate the effect of bevacizumab infusion on vascular parameters assessed by dynamic contrast-enhanced magnetic resonance (DCE-MR)…”
Get full text

P2-09-02: Predicting Response to Bevacizumab in Primary Breast Cancer Using 18F-Fluorothymidina (FLT) and 18F-Misonidazole (MISO) Positron Emission/Computed Tomography (PET/CT) as Imaging Biomarkers by Dominguez, I, Boni, V, Garcia-Velloso, MJ, Lopez-Vega, JM, Martinez, P, Plazaola, A, Llombart, A, Anton, A, Galve, E, Alvarez, IM, Hernando, B, Sanchez-Gomez, R, Illarramendi, JJ, Morales, S, De, Juan A, Richter, JA, Lahuerta, A, Garcia-Gonzalez, M, Lao, Romera J, Puertolas, T, Scherer, S, Sabariz, Luis, Garcia-Foncillas, J

“…Abstract Background: To investigate the hypothesis that early changes in tumor proliferation and hypoxic status induced by bevacizumab and assessed by imaging…”
Get full text

Update on adjuvant hormonal treatment of early breast cancer by Lao Romera, Juan, Puertolas Hernández, Teresa de Jesús, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José Juan, Garcerá Juan, Salvador, Ciruelos Gil, Eva María

“…Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal…”
Get full text

2110 Evaluation of response to sorafenib treatment in advanced hepatocellular carcinoma (HCC): role of Positron Emission Tomography (PET) imaging by Cid, R. Pazo, Romera, J. Lao, Lanzuela, M, Fuentes, J, Barrao, E, Sarria, L, Hordnler, C, Ubieto, M.A, Serrablo, A, Anton, A

Get full text

1100 Peripheral blood lymphocite populations in advanced gastric cancer patients have predictive and prognostic value by Cid, R. Pazo, Romera, J. Lao, Lanzuela, M, Gil, I, Godoy, A, Fernandez-Mosteirin, N, Madani, J, Lecumberri, M.J, Alejandro, M. Alvarez, Antó, A

Get full text

Update on adjuvant hormonal treatment of early breast cancer by Lao Romera, Juan, Puertolas Hernández, Teresa de Jesús, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José Juan, Garcerá Juan, Salvador, Ciruelos Gil, Eva María

Get full text

6581 Von willebrand factor and fibrinogen levels predict outcome in advanced gastric cancer patients by Pazo-Cid, R, Godoy, A, Romera, J. Lao, Fernandez-Mosteirin, N, Puértolas, T, Calderero, V, García-Foncillas, R, Lucia, J.F, Lecumberri, M.J, Antón, A

Get full text